logo
Global honour for drive led by Kolkata doctor against steroid misuse

Global honour for drive led by Kolkata doctor against steroid misuse

Time of India11-07-2025
1
2
Kolkata: A group of Indian doctors with Kolkata-based dermatologist, Koushik Lahiri, as its founding chairman has been felicitated by the Royal College of Physicians (RCP), London for their work against steroid abuse in fairness and other skincare products, including ointments.
The group, Indian Association of Dermatologists, Venereologists, and Leprologists Task Force against Topical Steroid Abuse (ITATSA), is among the three organisations that has been honoured with the 'RCP Excellence in Patient Care Awards' for 2025.
It had submitted its project titled 'A Crusade Against Abuse of Topical Steroid in India: A Silent Epidemic of Astronomical Magnitude' to RCP.
You Can Also Check:
Kolkata AQI
|
Weather in Kolkata
|
Bank Holidays in Kolkata
|
Public Holidays in Kolkata
Lahiri represented the organisation at an award ceremony held in Liverpool on July 10.
The Kolkata doctor has claimed that their campaign, spanning about two decades, has led to reduced sales of steroid-laden fairness and antifungal creams since 2018.
Health experts said a good number of skincare products contain an irrational mix of steroids and heavy metals with various harmful chemicals.
The high-potency formulations and prolonged use can do more harm than good, experts claimed, adding that one of the most common side effects is the red skin syndrome.
by Taboola
by Taboola
Sponsored Links
Sponsored Links
Promoted Links
Promoted Links
You May Like
An engineer reveals: One simple trick to get internet without a subscription
Techno Mag
Learn More
Undo
ITATSA has been publishing study reports to raise public awareness on this matter. The RCP lauded the continuous efforts of ITATSA in combating steroid abuse since 2014.
"This crusade is not the work of one, but the outcome of the tireless efforts of hundreds of dermatologists across India," Lahiri told TOI from the UK.
"This honour, following a detailed entry and presentation before an international jury, brings our work on Topical Steroid Damaged Face (TSDF) and the broader issue of irrational steroid misuse into the global spotlight," Lahiri added.
The core members of the organisation are doctors Arijit Coondoo from Kolkata, Rajetha Damishetty from Hyderabad, Shyam Verma from Vadodara, Rajeev Sharma from Aligarh, and Abir Saraswat from Lucknow. In fact, Damishetty was with Lahiri for the award ceremony.
The other two organisations, which received the honour, were Croydon University Hospital and Homerton Healthcare Trust, both based in the UK.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Gland Pharma Q1 profit jumps 50% on core growth, Cenexi turnaround
Gland Pharma Q1 profit jumps 50% on core growth, Cenexi turnaround

Business Standard

time12 minutes ago

  • Business Standard

Gland Pharma Q1 profit jumps 50% on core growth, Cenexi turnaround

Hyderabad-based Gland Pharma reported a 50 per cent increase in its consolidated net profit year-on-year (Y-o-Y), reaching ₹215 crore for the first quarter of the financial year (Q1FY26). Revenue from operations rose 7 per cent Y-o-Y to ₹1,505 crore. The growth was driven by robust performance in its core business and a successful turnaround at Cenexi, a French pharmaceutical contract development and manufacturing organisation (CDMO) specialising in sterile injectable and lyophilised drug products, which Gland Pharma acquired in 2023. Sequentially, the company's net profit rose by 15 per cent, and revenue increased by 6 per cent. 'We're off to a positive start this year with growth in revenue and a jump in profitability. Our strategic priorities are progressing and we are strengthening our capabilities, adding new capacity, and boosting R&D with complex products and key partnerships,' said Srinivas Sadu, executive chairman, Gland Pharma. 'By enhancing our base business, investing in differentiated products and driving operational efficiencies, we are positioning ourselves for sustained growth. Our focus on adherence to global quality standards and investment in capability building position us to scale further, tap new markets and deliver long-term value,' said Shyamakant Giri, chief executive officer, Gland Pharma. During the quarter, research and development (R&D) expenses stood at ₹46 crore, accounting for 4.4 per cent of revenue. The company launched 12 new molecules in regulated markets, including Colistimethate, Epinephrine, Vancomycin (three new strengths), Liraglutide and Acetaminophen bags. One abbreviated new drug application (ANDA) was filed and nine were approved during the quarter, bringing cumulative US ANDA filings to 372 (325 approved and 47 pending). Its in-house complex pipeline saw six product launches, with three more awaiting approval. Complex injectables remain a key driver of long-term growth, with more products being added to the pipeline. Fifteen products are in co-development (seven under the 505(b)(2) pathway and eight ANDAs), with commercialisation expected to begin in FY28. One ready-to-use (RTU) infusion bag was filed this quarter, bringing the total RTU product filings in the US to 20 (14 approved). Another 10 are in development, targeting a $767 million market. The company expanded its GLP-1 portfolio, launching Liraglutide in the UK and Australia, and is increasing GLP-1/pen/cartridge capacity from 40 million to 140 million units. It also received a good manufacturing practice (GMP) compliance certificate from the Danish Medicines Agency for aseptically prepared powder for injection, infusion and inhalation. The results were announced after market hours. Gland Pharma's stock fell by 0.95 per cent, ending the day's trade at ₹1,962.30 per share on the BSE.

Farmers seek compensation for massive crop loss in Haryana due to virus outbreak, waterlogging
Farmers seek compensation for massive crop loss in Haryana due to virus outbreak, waterlogging

Time of India

time41 minutes ago

  • Time of India

Farmers seek compensation for massive crop loss in Haryana due to virus outbreak, waterlogging

KURUKSHETRA: In an appeal to Haryana chief minister (CM) Nayab Singh Saini, Bharatiya Kisan Union (BKU) Charuni representatives from across the state have demanded immediate compensation for the losses incurred due to a virus outbreak in paddy crops and widespread waterlogging caused by excessive rainfall. In a letter addressed to CM Saini, BKU Charuni the farmers highlighted that this year, paddy crop across thousands of acres in multiple districts—including Karnal, Kurukshetra, Ambala, Yamunanagar, Kaithal, Jind, Panipat, Rohtak, and Sonipat—have been severely affected by two viral diseases: Southern Rice Black Streak Dwarf Virus (SRBSDV) and Rice Gall Dwarf Virus (RGDV) . These diseases have resulted in stunted plant growth and root rot, rendering entire fields barren. According to agricultural experts, the virus outbreak is a relatively new phenomenon in the region and beyond the control of the farming community. Scientific surveys have confirmed the presence of these viruses and attributed the crop damage directly to them. In addition to the viral infestation, prolonged monsoon rains have caused waterlogging in fields, further compounding the crisis. This dual blow has left hundreds of farmers—both small and large landholders—facing serious financial distress. Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Blood cancer is taking our curious baby away from us! Donate For Health Donate Now Undo by Taboola by Taboola In their petition, the farmers have made two key demands: Proactive Government Intervention: The state government should take immediate and long-term steps to improve crop protection, seed quality, and disease control mechanisms to prevent such disasters in the future. Transparent Loss Assessment and Compensation: Authorities must conduct a fair, transparent, and prompt survey of the losses caused by both the virus and waterlogging. Based on this assessment, adequate compensation should be disbursed to all affected farmers without delay. Calling the situation 'unprecedented,' the letter urges CM Saini to take swift action to relieve the suffering of Haryana's farming community and ensure their financial recovery. The appeal comes at a time when farmers across the state are already reeling from rising input costs and unpredictable weather patterns, further underlining the urgent need for government support.

Eris Lifesciences to target insulin, semaglutide mkt opportunities in FY26
Eris Lifesciences to target insulin, semaglutide mkt opportunities in FY26

Business Standard

timean hour ago

  • Business Standard

Eris Lifesciences to target insulin, semaglutide mkt opportunities in FY26

Ahmedabad-based Eris Lifesciences is looking to target opportunities in the nearly ₹5,000-crore Indian insulin market after Danish drugmaker Novo Nordisk announced a withdrawal of its insulin products in April this year. For Q1FY26, Eris Lifesciences recorded a 40 per cent year-on-year (Y-o-Y) rise in consolidated profit after tax (PAT) to ₹125 crore. Revenue rose to ₹773 crore during the June quarter against ₹720 crore in the year-ago period. 'We expect that Novo's cartridge inventory in the market will run out by October. So this market opportunity is something that one can start monetising from the November-December time frame,' the company's executive director and chief executive officer (CEO) Krishnakumar Vaidyanathan told Business Standard. He added that the timing fits Eris' plans as its Bhopal unit's cartridge filling capability will start getting operational from January. Vial manufacturing has already been commissioned at the Bhopal unit, with the company creating a strategic stock of insulins. This comes at a time when Eris already is the largest domestic player in insulin. The company had last year acquired the India formulations business of Biocon Biologics last year, including established insulin brands Basalog and Insugen. 'Before the Biocon deal, we had a couple of homegrown insulin brands in the market, which did a combined ₹60 crore in revenue last year. Basalog and Insugen had combined revenues of ₹200 crore at the time of acquisition,' he said. He added that with this, the company's insulin franchise has become really large with a 10 per cent market share. Eris is also among the prominent drugmakers looking to roll out generic versions of blockbuster molecule semaglutide once its patent expires around March next year. Semaglutide is a GLP-1 (glucagon-like peptide 1) receptor agonist that is used as an active pharmaceutical ingredient in medications for obesity management and Type-II diabetes. According to Eris' investor presentation for the June quarter of the financial year 2025-26 (Q1FY26), the company is on track to be among the first launches in India in March 2026. The company has initiated validation of synthetic semaglutide cartridges at its European Union (EU)-approved AMD injectables site. 'We are also planning the validation of the recombinant semaglutide in our Bhopal plant later this year,' he added. As far as the go-to market is concerned, the company said it is already in a strong position because of its dominant position in insulins and prior presence in the GLP market with the launch of Liraglutide in September last year.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store